NCT00522925

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 280 (actual)
• Sponsor: Ligand Pharmaceuticals · Industry
• Sex: All
• Age: 30 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	PS433540	200mg capsule, once daily for 28 days
DRUG	placebo	placebo capsule, once daily for 28 days
DRUG	PS433540	500mg capsule, once daily for 28 days

Timeline

• Start date: 2007-08-01
• Primary completion: 2008-04-01
• Completion: 2008-05-01
• First posted: 2007-08-30
• Last updated: 2011-09-16
• Results posted: 2011-09-14

Locations

15 sites across 1 country: United States